About Us

Ellca Ratther

Ellca Ratther


  • PhD Candidate, APCRC-Q (Cancer Plasticity)
  • Member, IHBI, Queensland University of Technology

Contact Details

+61 7 3443 7265


BSc, Biology, University of British Columbia, Canada, 2014


Ms Ellca Ratther joined the Australian Prostate Cancer Research Centre- Queensland (APCRC-Q) at Queensland University of Technology’s Institute of Health and Biomedical Innovation as a PhD student. Ellca completed a BSc in Biology at the University of British Columbia (UBC) in 2014 where she took part in the science cooperative education program and did a seven month placement at the APCRC-Q. Under the supervision of Dr Brett Hollier, Associate Professor Elizabeth Williams, Dr Katrina Sweeney and Professor Colleen Nelson, Ellca is investigating the role of epithelial plasticity in progression of castration resistant prostate cancer, specifically neuroendocrine transdifferentiation. Neuroendocrine prostate cancer is a lethal and highly aggressive disease and investigation of the adaptive pathways involved in developing this cancer could lead to development of biomarkers and targets for treatments.

Awards and grants


QUT Higher Degree Research Student Grant-in-Aid Travel Grant


NSERC Industrial Undergraduate Student Research Award (IUSRA)

Research interests

Prostate cancer, androgen signalling, EMT, neuroendocrine transdifferentiation, treatment resistance mechanisms, androgen targeted therapies

Current research projects

Investigating the role of epithelial plasticity during prostate cancer progression.

Top publications

Tse BWC*, Volpert M*, Ratther E*, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG. Neuropilin-1 is up-regulated in the adaptive response of prostate tumours to androgen targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. 2017; 36(24): 3417-3427 (*Authors contributed equally).

Nouri M*, Ratther E*, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention. Frontiers of Oncology. 2014; 4:370 (*Authors contributed equally).

More publications are available on PubMed


Professional memberships and associations


American Association of Cancer Research


Australian Society of Medical Research


The EMT International Association


Australian Prostate Cancer Collaboration